Owing to the high chemoselectivity between an aminooxy function and a carbonyl group, oxime ligation is one of the most preferred procedures for the preparation of peptide conjugates. However, the sensitivity of (aminooxy)acetylated peptides to ketones and aldehydes makes their synthesis and storage difficult. In our study, we established the efficient synthesis of an (aminooxy)acetylated-somatostatin derivative in the presence of free (aminooxy)acetic acid, which was used as a 'carbonyl capture' reagent in the final cleavage step. This (aminooxy)acetylated compound was further used for the chemoselective ligation (oxime bond formation) with daunorubicin and 4-fluorobenzaldehyde leading to the formation of conjugates with potential applications in targeted cancer chemotherapy and positron emission tomography. Copyright
Introduction
Chemoselective ligation methods are commonly used for the preparation of peptide conjugates, as well as for the condensation of unprotected peptide fragments. Oxime ligation is one of the most preferred procedures, due to the high chemoselectivity between an aminooxy function and a carbonyl group [1, 2) . Formation of chemoselective oxime bonds has been successfully applied for the synthesis of various peptide conjugates [3, 4) , glycopeptides [5) , conjugates of DNA with different biomolecules [6) , oligonucleotide-peptide conjugates [7, 8) , and proteins from peptide fragments [9, 10) . Moreover, oxime ligation has recently been investigated for the preparation of 18F-labeled peptide conjugates [11, 12) and drug-peptide conjugates [13] [14] [15] . Furthermore, (aminooxy)acetic acid was incorporated into heterobifunctional linkers for facile synthesis of bioconjugates [16, 17) .
During the past decade, several side reactions have been reported to occur during synthesis, purification, and work-up procedures of (aminooxy)acetylated peptides [9, 10, 18) . One of them is the N-overacylation of the NH-O function, either during the incorporation of Boc-(aminooxy)acetic acid derivative (BocAoa) or through the peptide chain elongation. Carbodiimidemediated one-pot acylation without base [18) or the application of Boc-Aoa-OSu active ester as an acylating agent [19) , as well as the use of a high excess (8 equiv.) of Boc-Aoa-OH and coupling agents for a short acylation time (10 min) [20) might prevent the overacylation.
Another side reaction which has been less investigated and reported so far derives from the high reactivity of the free aminooxy group toward aldehydes and ketones leading to the formation of unwanted side products [9) . (Aminooxy)acetylated peptides can react with traces of acetone or formaldehyde (e.g. from the softeners of the plastic tubes) not only during the reaction steps (cleavage, ligation) but also under the HPLC purification conditions and even during the storage of the purified peptides. Bure et al. identified the main side products that were formed during oxime ligation of peptides [10) . Using [11] and of a templateassembled cyclic RGD peptide conjugate [21] . However, it was mentioned that a fivefold higher peptide concentration was needed for the efficient labeling in comparison with the unprotected (aminooxy)acylated peptides. Careful handling of unprotected Aoa-containing peptides, such as working under argon or nitrogen stream in an 'acetone-free' laboratory, using freshly distilled diethylether for precipitation [22] , shortening the work-up procedure, using methanol or freshly prepared acetonitrile solutions for HPLC purification, and storage of the compounds at temperatures below -20 cC in glass tubes might help avoid the unwanted side reactions. However, in some cases all of these precautions are not enough to prevent the formation of a large amount of side products.
In the present study, we provide evidence that free (aminooxy)acetic acid could serve as an efficient 'carbonyl capture' reagent if it is added to the cleavage mixtures used for the cleavage of (aminooxy)acetylated peptides from the resin. We employed this 'carbonyl capture' reagent for the synthesis of an (aminooxy)acetylated-somatostatin derivative which was further used for the preparation of daunorubicin-somatostatin and FBOA-somatostatin bioconjugates.
Recently, we have demonstrated the in vitro and in vivo antitumor activity of a daunorubicin -GnRH-1II derivative bioconjugate (GnRH: gonadotropin-releasing hormone) containing an oxime linkage between the components [13] . The formation of a side product (M + 40 Da) was observed after the cleavage of the GnRH-1II derivative (Glp-His-Trp-Ser-His-Asp-Trp-Lys(HAoa-Gly-Phe-Leu-Gly)-Pro-Gly-NH2) from the resin. However, the (aminooxy)acetylated peptide could be purified and further used for the attachment of daunorubicin via oxime ligation.ln contrast, the synthesis of H-Aoa-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2, an N-terminal Aoa-elongated version of RC -121 somatostatin analog developed in Schally's laboratory [23] was unsuccessful. Several synthetic procedures were employed; however, none of them led to the formation of the desired cyclic peptide. In spite of the careful work, oximes of the somatostatin derivative with acetone, acetaldehyde, and formaldehyde were almost quantitatively formed. Finally, this highly sensitive (aminooxy)acetylated peptide could efficiently be prepared in the presence of free Aoa as a 'carbonyl capture' reagent which was used during the removal of the N-terminal Boc protecting group.
Materials and Methods

Chemicals
All amino acid derivatives and Rink-Amide MBHA resin were purchased from IRIS Biotech GmbH (Marktredwitz, Germany) Boc-Aoa-OH and PcpOH (10 mmol each) were dissolved in 50 ml ethyl acetate and then an equivalent amount of DCC in 50 ml ethyl acetate was added to the solution (under cooling). The reaction mixture was stirred overnight at RT. The precipitated DCU was filtered out prior to the evaporation of the solvent. The remaining compound was recrystallized from methanol. The yield of the pure product was 72%. and (vi) ninhydrine assay. The peptide was cleaved from the resin using a mixture ofTFA-phenol-EDT-thioanisole-water (1 0 ml, 0.75 g, 0.25 ml, 0.5 ml, 0.25 ml) at RT for 1.5 h, then precipitated with cold diethyl ether, washed three times with diethyl ether, and solubilized in 100% acetic acid prior to freeze drying. By this cleavage procedure, all side-chain protecting groups were removed except for the ivDde from the side chain of Lys. The crude peptide was characterized by analytical RP-HPLC (Rt: 36.3 min) and ESI-MS (MWcal c / exp: 1253.60/1254.05). The compound was used in the next synthetic step without purification. From the Boc-protected linear peptide, the ivDde group was cleaved with 2% hydrazine in DMF. Under these cleavage conditions (peptide concentration of 1 mg/ml, RT, 60 min), not only was the protecting group removed but the disulfide bridge between the thiol groups of cysteines was also formed. The solvent was evaporated in vacuo and the crude peptide was purified by semipreparative RP-HPLC (47% yield). The purified compound was characterized by analytical RP-HPLC (Rt: 33.1 min) and ESI-MS (MWcalc/exp: 1218.6/1218.5). The cyclic peptide containing ivDde protecting group (Rt: 43.7 min) and the unprotected linear peptide (Rt: 30.9 minI were identified as main side products. A mixture of 10 mg somatostatin analog and Aoa was dissolved in 0.8 ml of 0.1% TFA (aqueous solution). The peptide was immobilized on a Sep-Pak" Plus (18 cartridge and the cartridge was flushed with 8 ml of 0.1% TFA in water. The peptide was eluted with 75% MeOH/O.l % TFA. The first fraction (0.6 ml) was discarded and the fractions containing the peptide analog were combined (1 ml). A solution of 0.62 mg 4-f1uorobenzaldehyde in 25 JlI MeOH was added (5 Jlmol) to this mixture and stirred for 60 min at 60"C The solution was cooled down to room temperature and then diluted with water to a final volume of 5 mL The labeled peptide analog was purified by semi preparative RP-HPLC The purity was higher than 97%and the amount of purified peptide conjugate that resulted was 3.2 mg. The yield could not be calculated due to the unknown composition of the starting mixture of the somatostatin analog and Aoa. The conjugate was characterized by analytical HPL( (Rt: 12.9 min) and MALDI-MS (MWcal c / exp: 1224.5/1224.6).
High performance liquid chromatography (HPLC)
Analytical RP-HPL( was performed on a Knauer (H. Knauer, Bad Homburg, Germany) system using a Phenomenex Jupiter 
Mass spectrometry (MS)
Mass spectrometricanalyses were carried outon a Bruker Daltonics Esquire 3000+ ion trap mass spectrometer (Bremen, Germany). Spectra were acquired in the 50-2000 m/z range. Samples were dissolved in acetonitrile-water = 1: 1 (v/v) solvent mixture containing 0.1% acetic acid.
The mass spectrometric analysis of FBOA-somatostatin conjugate was performed on a Bruker Biflex-III MALDI-TOF mass spectrometer (Bremen, Germany) using 2,5-dihydroxy benzoic acid (DHB) as a matrix. serum, Sigma Ltd.), L-glutamine (2 mM), gentamicin (160 ~g/ml) at 37 cC in a humidified 5% C02 atmosphere. HT-29 human colon adenocarcinoma cell line was cultured in RPMI-1640 (Sigma Ltd.) containing 10% FCS, L-glutamine (2 mM), and gentamicin (160 ~g/ml) at 37°C in a humidified 5% C02 atmosphere. NCI-H358 human non-small cell lung cancer cell line was maintained in RPMI-1640 containing 10% FCS and L-glutamine (2 mM) at 37 GC in a humidified 5% C02 atmosphere.
In vitro cytostatic effect of compound §. determined by MTI assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay)
To study the in vitro cytostatic effect of com pound §., MCF-7 h u ma n breast, HT-29 human colon and NCI-H358 human non-small cell lung cancer cells were plated into 96-well tissue-culture plate in 100 ~I culture medium with the initial cell number of 5 x 10 3 cells/well. The compounds used in the 5 x 10-4 -2 x 10 2 flM concentration range were dissolved in fresh culture medium and added to the cells. After treatment and incubation (6 h in case of NCI-H358 cells or 16 h in case of MCF-7 and HT-29 cells) at 37°C, cells were washed twice with serum-free medium and cultured in serum-containing medium for 72 h. The amount of the living cells was determined by MTT assay using 0.367 mg/ml final concentration of MTT in each well. After 3.5 h incubation with MTT, cells were centrifugated at 2000 rpm for 5 min, supernatant was removed and crystals were dissolved in DMSO. The absorbance was measured using an ELlSA-reader (Labsystems MS Reader, Finland) at A = 540 nm and at ). = 620 nm as reference wavelength.
Statistical data analysis was performed by Student's Hest of Origin7.5 at the 95% confidence level.
Results and Discussion
Hormonal peptides such as somatostatin, GnRH, and their derivatives are applied for targeting drugs and radionuclides to cancer cells [24, 25] . One approach to attach drugs or isotope-containing organic compounds to peptides is oxime ligation between an (aminooxy)acetylated peptide and an oxo group. However, the sensitivity of the aminooxy moiety to other oxo group containing compounds like acetone, formaldehyde and so on makes the synthesis and storage of Aoa-peptides difficult. The major goal of our work was to prepare oxime bond-linked daunorubicin-somatostatin and FBOA-somatostatin conjugates for targeted cancer chemotherapy and positron emission tomography (PET) (Figure 1 ) using daunorubicin or 4-fluorobenzaldehyde and H-Aoa-D-Phe-c[C ys-Tyr-D-T rp-Lys-Va I-CysJ-Thr-NH2, anN-term inal Aoa-elongated version ofRC-121 somatostatin analog. Forthis purpose, the peptide was initially purchased from a supplier; however, the received compound had a molecular mass with 40 Da higher than the calculated one, modification that might derive from the oxime bond formation between acetone and Aoa-peptide (according to the literature data [10] ). Therefore, we decided to synthesize the peptide by ourselves. The somatostatin analog was built up by SPPS on a Rink-Amide MBHA resin followed by the cleavage with TFA in the presence of appropriate scavengers and reducing agents (water, phenol, thioanisole, EDT). Surprisingly, the crude product obtained after lyophilization (liquid nitrogen was used for freezing the sample) was characterized by one main HPLC peak corresponding to the acetone-modified peptide (M + 40 Da mass). In the next trial, the somatostatin derivative without Aoa was prepared using ivDde protecting group on the side chain of Lys (Figure 2 ). The peptide was cyclized by air oxidation, followed by the coupling of Boc-Aoa-OH to the cyclic peptide using BOP reagent. The reaction resulted in the Aoa-containing cyclic somatostatin derivative with a very low yield. Finally, Boc-Aoa-OPcp prepared in our laboratory was connected to the linear semiprotected peptide chain (Boc-Aoa-D-Phe-Cys-Tyr-D-Trp-Lys(ivDde)-Val-Cys-Thr-NH2) (Scheme 1). The cleavage of ivDde protecting group with 2% hydrazine in DMF resulted not only in the removal of the protecting group but also in the cyclization of the somatostatin derivative ( Figure 3(A) ; compound with a retention time of 33.1 min). The Boc group from the cyclic compound was cleaved with TFA in the presence of 5% water using argon flushed glass wears followed by precipitation with diethylether. The RP-HPLC profile of the crude product after lyophilization showed four peaks that corresponded to the expected cyclic peptide (Rt: 26.4 min) and oxime derivatives with + 12 Da, +26 Da, and +40 Da molecular masses (Figures 3(B) and 4). The crude peptide was purified by RP-HPLC using methanol as a major component of eluent B. However, the separated fraction corresponding to the expected product (fraction 1, Rt: 26.4 min) turned to the acetone-modified one very fast and no other compound could be detected by MS after lyophilization (Figure 4) . The chemical modification of the expected product was also confirmed by the change of the retention time (Rt: 29.8 min), which was identical with that of the acetone-modified compound (fraction 4, Figure 4 ). To overcome the unwanted oxime bond formation under the cleavage conditions and during the work-up procedure, 10 equiv. of free (aminooxy)acetic acid were added to the cleavage mixture used to remove the Boc group of the cyclic somatostatin derivative (Scheme 1). The HPLC profile of the resulted crude product showed only one main peak (Figure 3(C) ) which corresponded to the expected product as determined by mass spectrometry (Figure 3(D) ). The work-up procedure (precipitation with dry diethylether, solubilization in acetic acid, and lyophilization) did not result in the removal of the Aoa excess from the peptide; therefore, the compounds could be kept for months at +4 cC without detecting any significant modification. However, the excess of Aoa should be removed prior to the chemical ligation in order to avoid the reaction of carbonyl-containing compounds with free Aoa. For this purpose, the mixture containing Aoa-peptide and free Aoa was purified by RP-HPLC using methanol as eluent B, followed by an immediate evaporation of the solvent from the collected peptide fraction. The resulting material was dissolved in 0.2 M NaOAc, pH = 5 and added to daunorubicin. The ligation was completed in 3 h ( Figure 5 ; it is also important to note the fragmentation of the glycosidic bond during the mass spectrometric analysis resulting in the loss of daunosamine).
In another application, the peptide was dissolved in 0.1% TFA (aqueous solution) and immobilized on a Sep-Pak® Plus C18 cartridge. The somatostatin derivative was eluted with 75% MeOH solution containing 0.1% TFA and the peptide containing fraction was mixed directly with the MeOH solution of 4-fluorobenzaldehyde. The ligation continued at 60 QC for 60 min resulting in the expected FBOA-somatostatin derivative.
In vitro cytostatic activity of oxime bond-linked daunorubicin-somatostatin conjugate was determined on MCF-7 human breast, HT-29 human colon, and NCI-H358 human lung cancer cell lines by MTI assay. The cytostatic effect of the daunorubicin-somatostatin conjugate (presented as IC so values in Table 1 (1-20 IlM) than that of free daunorubicin (0.1-2IlM). The data are similar to those obtained in the case of oxime bond containing Dau-GnRH-11I conjugates [13, 26] that have been already shown to have in vivo antitumor effect without significant toxic side effects. The results reported here are promising and provide a basis forthe further investigation of the in vivo antitumor activity of this novel Dau-somatostatin conjugate.
Conclusions
Oxime ligation is a chemoselective procedure most commonly used for the preparation of peptide conjugates. However, the sensitivity of (aminooxy)acetylated peptides to ketones and aldehydes makes their synthesis and storage difficult. Therefore, in order to prevent the unwanted modifications of highly sensitive Aoa-peptide derivatives, we investigated the application of free (aminooxy)acetic acid as a 'carbonyl capture' reagent to be used in the final cleavage step and during the work-up procedure and storage. In the presence of free (aminooxy)acetic acid, an Aoa-somatostatin derivative could be efficiently prepared and used for further chemoselective ligation with daunorubicin and 4-fluorobenzaldehyde leading to the formation of conjugates with potential applications in targeted cancer chemotherapy and PET. The oxime bond-linked daunorubicin-somatostatin conjugate has in vitro cytostatic activity on various cancer cell lines, such as MCF-7 human breast, HT-29 human colon, and NCI-H358 human lung cancer cell lines.
